About Motac
Motac is a company based in Manchester (United Kingdom) founded in 1999. Motac offers products and services including Preclinical Services, In Vivo Services, and Ex Vivo Services. Motac operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
- Headquarter Manchester, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$774.93 K (USD), Grant
Jan 01, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Motac
Motac offers a comprehensive portfolio of products and services, including Preclinical Services, In Vivo Services, and Ex Vivo Services.
Provides studies for efficacy testing in neurological disorders
Conducts live animal tests for drug development in diseases
Offers tissue-based analysis for therapeutic research
Funding Insights of Motac
Investors in Motac
Motac has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Motac
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Motac
Investment portfolio details for Motac
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Motac
Detailed financials for Motac
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Motac Comparisons
Peer comparison for Motac
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Motac
Motac operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapies for psychosis and cognitive impairment are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Motac
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Motac
Complete news archive for Motac
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Motac
Motac was founded in 1999 and raised its 1st funding round 21 years after it was founded.
Motac is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Alan Crossman is the current CEO of Motac.
Motac supports pharma companies working on neurological and psychiatric disorders, particularly Parkinsons disease, other movements, and cognitive disorders. It helps in designing in-vivo and ex-vivo animal models and also provides contract screening services. In addition, Motac has a portfolio of patents and patent applications based on novel dopamine D3 receptor agonists, μ opioid receptor antagonists, 5-HT1a receptor agonists for the treatment of Parkinsons disease and Dyskinesia.
Motac's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
Motac offers Preclinical Services, In Vivo Services, and Ex Vivo Services.
Motac has 1 investor. Key investors include European Union.